Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

@article{Kerr2007RofecoxibAC,
  title={Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.},
  author={David James Kerr and Janet. A. Dunn and Michael John Stratton Langman and Justine L. Smith and Rachel S J Midgley and Andrew Stanley and Joanne C Stokes and Patrick Julier and Claire Iveson and Ravi Duvvuri and Christopher C. McConkey},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 4},
  pages={
          360-9
        }
}
BACKGROUND Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, started… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS, ESTIMATED Infinity% COVERAGE

56 Citations

0510'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 56 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Similar Papers

Loading similar papers…